|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
As a result, we observed higher level of XIST and Smurf1, but lower level of miR-27a in SCI rats and lipopolysaccharide (LPS)-induced primary microglial cells. in vitro, LPS induced SCI microglia cells as described by decreased cell viability and B cell lymphoma 2 (Bcl-2) expression, and increased cell apoptosis rate, Bax and cleaved caspase 3 levels, and tumor necrosis factor α (TNF-α) and interleukin 6 (IL-6) secretions. in vivo, a T10 laminectomy caused SCI rats as evidenced by decreased Basso-Beattie-Bresnahan Locomotor Rating Scale (BBB) score and induced expression of Bax, cleaved caspase 3, TNF-α and IL-6.
|
31778769 |
2020 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The mRNA expression of Tfh cell transcription factors and functional molecules such as B-cell lymphoma 6 (Bcl-6), B lymphocyte maturation protein 1 (Blimp-1), IL-6, IL-21, IL-12 and IFNγ in the joints of CIA mice were detected by real time PCR (RT-PCR).
|
31025923 |
2020 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Systemic administration of C-miR146a oligonucleotide alleviated human monocyte-dependent release of IL-1 and IL-6 in xenotransplanted B-cell lymphoma model without affecting CD19-specific CAR T-cell antitumor activity.
|
31805184 |
2020 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MCAO mice showed overexpression of interleukin-6 (IL-6), IL-17, and IL-23, and increased positive protein expression of PTGS2, as well as expression of PTGS2, nuclear factor-κB (NF-κB), tumor suppressor region 1 (TSP-1) and Bcl-2-associated X protein (Bax), but underexpression of vascular endothelial growth factor (VEGF), S-phase kinase associated protein 2 (Skp2), and B-cell lymphoma 2 (Bcl-2).
|
31222746 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Compared with those in the model group, the necrosis of bone tissues significantly decreased, the apoptosis level of osteocytes remarkably declined (p<0.01), the content of IL-1β, IL-6 and TNF-α in bone tissues markedly decreased (p<0.01), the content of IL-10 increased (p<0.01), the expression level of cleaved caspase-3 protein in bone tissues significantly declined (p<0.01), the B-cell lymphoma 2/BCL2-Associated X (Bcl-2/Bax) expression level markedly increased (p<0.01) and the expression levels of ALK3, GATA4 and NKX2.5 in bone tissues significantly decreased (p<0.01) in the intervention group.
|
31210286 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our results show that Shuxuetong injection increases bEnd.3 cell viability and B-cell lymphoma 2 expression, reduces cleaved caspase-3 expression, inhibits production of reactive oxygen species and mitochondrial superoxide, suppresses expression of tumor necrosis factor alpha, interleukin-1β, interleukin-6, inducible nitric oxide synthase mRNA, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1, markedly increases transepithelial resistance, decreases blood-brain barrier permeability, upregulates claudin-5, occludin, and zonula occludens-1 expression, reduces nuclear factor-κB p65 and vascular endothelial growth factor expression, and reduces I kappa B alpha, extracellular signal-regulated protein kinase 1/2, and I kappa B kinase phosphorylation levels.
|
30688264 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Levels of interferon γ (IFN-γ), interleukin 10 (IL-10), interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), creatine kinase (CK), lactate dehydrogenase (LDH), superoxide dismutase (SOD) and malondialdehyde (MDA) were detected, and expression of miR-203, MYD88, toll-like receptor 4 (TLR4), Faslg, Cleaved-Caspase-3, B-cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) was evaluated.
|
30772517 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Blood and cerebral tissues were collected, cerebral pathological injuries and infarct sizes were investigated, serum interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) levels were measured, the activities of superoxide dismutase (SOD) and ROS were calculated, the contents of methane dicarboxylic aldehyde (MDA), IL-6, TNF-α and hemodynamic change were estimated, and expression levels of b-cell lymphoma-2 (Bcl-2), bcl-2-associated x (Bax), BMP-4 and COX-2 were assessed in cerebral tissues.
|
31113339 |
2019 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Vaccarin treatment attenuated hypertension, reduced fibrosis markers, NADPH oxidase (NOX)-2, NOX-4, 3-nitrotyrosine, tumor necrosis factor-α, interleukin 1β (IL-1β), and IL-6 protein levels and altered pro-apoptotic protein levels including caspase-3, anti-apoptosis protein B cell lymphoma (Bcl)-2 and Bcl-2 associated X, apoptosis regulator in the right kidney of 2K1C rats.
|
29399101 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Western blot of lung tissue confirmed high expression of KGF and their target molecules (interleukin-6, protein kinase B, and B-cell lymphoma-2) in the Muse group.
|
29707971 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, changes in expressions of pro-inflammatory cytokines (tumour necrosis factor-α, interleukin-1β, interleukin-6) and apoptosis-related proteins (B-cell lymphoma-2, caspase-3) which indicated "inflammaging", might contribute to the loss of enteric neurons and interstitial cells of Cajal in aged gastrointestinal tract.
|
30530917 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Compared with the myocardial injury following ischemia‑reperfusion group, umbelliferone significantly prevented myocardial injury, inhibited oxidative stress markers (superoxide dismutase and malondialdehyde), reduced inflammation (tumor necrosis factor‑α and interleukin‑6) and myocardial apoptosis levels (caspase‑3/9 and apoptosis regular B‑cell lymphoma‑2‑associated X protein) in the myocardial injury following ischemia‑reperfusion group of rats.
|
29257247 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, siRNA‑ANXA1 upregulated the levels of B‑cell lymphoma‑2 (Bcl‑2) and pro‑caspase‑3, and downregulated the levels of Bcl‑2‑associated X protein, cleaved‑caspase‑3, TNF‑α, IL‑1β, IL‑6 and IL‑8.
|
30272262 |
2018 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The concentration of creatine kinase (CK), tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 were determined; the levels of total and phosphorylated glycogen synthase kinase 3 beta (p-GSK3β) and B-cell lymphoma 2 (Bcl-2) were quantified by western blotting, and the rate of apoptosis was assessed by terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick end labeling (TUNEL) staining.
|
27771871 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Percentages of terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL)-positive, cleaved caspase-3-, -8-, and -9-positive cells, the ratio of Bcl-2-associated X protein (Bax) to B-cell lymphoma 2 (Bcl-2), and expressions of inflammatory cytokines (tumor necrosis factor-α, interleukin-6) were decreased by PDRN treatment in the LPS-induced lung injury rats.
|
28837114 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Changes in the peripheral hemogram, thymus and spleen indices, DNA content in the bone marrow, interleukin (IL)-2 and IL-6 levels, and the expression levels of B cell lymphoma 2 (Bcl-2) and Bcl-2-associated X protein (Bax) following irradiation were assessed.
|
29285056 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
The levels of tumor necrosis factor-alpha (TNF-α), interleukin (IL-6), myeloperoxidase (MPO), p38 mitogen-activated protein kinase (p38MAPK), Bax, and B-cell lymphoma 2 (Bcl-2) were also evaluated.
|
28550734 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpression of Ascl2 also increased the expression of proinflammatory cytokines and chemoattractants including interleukin 6 (IL-6), tumor necrosis factor-α, IL-8, programmed cell death 1 (PD-1), IL-21, and B-cell lymphoma 6 (Bcl-6).
|
28728856 |
2017 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Additionally, the mRNA expression levels of interleukin- (IL-) 21, IL-6, and transcriptional factors (B-cell lymphoma-6, Bcl-6) were also significantly increased in peripheral blood from acute HSP children compared to HCs.
|
26491701 |
2015 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor risk was associated with higher tumor necrosis factor-α and insulin and altered oxidative stress biomarkers in sera and with early changes in mammary expression of genes linked to tumor promotion [interleukin 6 (Il6)] or inhibition [phosphatase and tensin homolog deleted on chromosome 10 (Pten), B-cell lymphoma 2 (Bcl2)].
|
24832086 |
2014 |
|
B-Cell Lymphomas
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Interleukin-6 plasma levels are modulated by a polymorphism in the NF-κB1 gene and are associated with outcome following rituximab-combined chemotherapy in diffuse large B-cell non-Hodgkin lymphoma.
|
21902578 |
2012 |
|
B-Cell Lymphomas
|
0.100 |
AlteredExpression
|
group |
LHGDN |
Correlation of serum IL-6, IL-8 and IL-10 levels with clinicopathological features and prognosis in patients with diffuse large B-cell lymphoma.
|
18479302 |
2008 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
Increased secretion of IL-6 via stimulation of TLR2 by HCV core protein may play a role in the pathogenesis of hepatitis C-associated MC and B-NHL.
|
16899594 |
2006 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
This work describes the effects of the recombinant or adenovirally-delivered IL-6 superantagonist Sant7, anti-IL-6 and IL-6 receptor monoclonal antibodies in a severe murine model of human B-cell lymphoma induced in SCID mice by transplantation of an LCL-41 cell line variant (isotype-switched IgM>IgG).
|
16061391 |
2005 |
|
B-Cell Lymphomas
|
0.100 |
Biomarker
|
group |
BEFREE |
We suggest that IFN decreases apoptosis by mechanisms involving enhanced IL-6 and Bcl-2 levels, decreased TNF alpha and the down regulation of apoptotic oncogenes, including c-myc.
|
11755467 |
2002 |